Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: The impact of social network factors, side effects, and perceived treatment efficacy

Women and Health

Volumn 42, Issue 1, 2005, Pages 99-115

  Demas, Penelope A ^a   Thea, Donald M ^b   Weedon, Jeremy ^b   McWayne, Janis ^b   Bamji, Mahrukh ^c   Lambert, Genevieve ^d   Schoenbaum, Ellie E ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b Health Research Association   (United States)

^c METROPOLITAN HOSPITAL CENTER   (United States)

^d BRONX LEBANON HOSPITAL CENTER   (United States)

Author keywords

Adherence; HIV; Women

Indexed keywords

BIOLOGICAL MARKER; ZIDOVUDINE; ZIDOVUDINE GLUCURONIDE;

ADULT; ANEMIA; ARTICLE; BLOOD ANALYSIS; COPING BEHAVIOR; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG URINE LEVEL; DRUG USE; EMOTIONAL DISORDER; FATIGUE; FEMALE; FETOTOXICITY; HAIR LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTERVIEW; MAJOR CLINICAL STUDY; MEGALOCYTOSIS; NAIL DISEASE; NAUSEA; NERVOUSNESS; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PREGNANCY; PRENATAL CARE; SELF DISCLOSURE; SKIN MANIFESTATION; SOCIAL NETWORK; STRESS; SUPPORT GROUP; URINALYSIS; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADULT; ANTI-HIV AGENTS; ATTITUDE TO HEALTH; DISEASE TRANSMISSION, VERTICAL; DISTRICT OF COLUMBIA; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LOGISTIC MODELS; PATIENT COMPLIANCE; PATIENT DROPOUTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SOCIAL SUPPORT; ZIDOVUDINE;

EID: 33645570668     PISSN: 03630242     EISSN: 15410331     Source Type: Journal    
DOI: 10.1300/J013v42n01_06     Document Type: Article

References (35)

1. Catz, S. L., Kelly, J. A., Bogart, L. M., Benotsch, E. G., & McAuliffe, T. L. (2000). Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychology, 19, 124-133.
2. Centers for Disease Control and Prevention (1992). 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Mortality and Morbidity Weekly Review, 41, 1-19.
3. Centers for Disease Control and Prevention (1994). Zidovudine for the prevention of HIV transmission from mother to infant. Morbidity and Mortality Weekly Report, 43, 285-287.
4. Centers for Disease Control and Prevention (1995). U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. Mortality and Morbidity Weekly Report, 44 (RR-7), 1-15.
5. Centers for Disease Control and Prevention (2002). U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Morbidity and Mortality Weekly Report, 51, 1-38.
6. Cohen, S., Doyle, W. J., Skoner, D. P., Rabin, B. S., & Gwaltney, J. M. (1997). Social ties and susceptibility to the common cold. Journal of the American Medical Association, 277, 1940-1944.
7. Colon-Otero, G., Menke, D., & Hook, C. C. (1992). A practical approach to the differential diagnosis and evaluation of the adult patient with macrocytic anemia. In M.S. Wheby (Ed.), The Medical Clinics of North America: Anemia (pp. 581-598). Philadelphia: W. B. Saunders.
8. Cooper, E. R., Nugent, R., Diaz, C., Pitt, J., Hanson, C., Kalish, L. et al. (1996). After AIDS Clinical Trial 076: The changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of Human Immunodeficiency Virus in a cohort of infected women and their infants. Journal of Infectious Diseases, 174, 1207-1211.
9. Cooper, E. R., Charurat, M., Mofenson, L., Hanson, I. C., Pitt, J., Diaz, C. et al. (2002). Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 29, 484-494.
10. Demas, P. A., Webber, M. P., Schoenbaum, E. E., Weedon, J., McWayne, J., Enriquez, E. et al. (2002). Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: A preliminary study. Pediatrics, 110, e35.
11. Dunkel-Schetter, C., Gurung, R. A. R., Lobel, M., & Wadhwa, P. D. (2004). Stress processes in pregnancy and birth: Psychological, biological, and sociocultural influences. In A. Baum, T. A. Revenson, & J. E. Singer (Eds.), Handbook of health psychology (pp. 495-518). Mahwah, N.J.: Lawrence Erlbaum.
12. Duong, T., Piroth, L., Peytavin, G., Forte, F., Kohli, E., Grappin, M. et al. (2001). Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: Relationship to virologic response. Clinical Infectious Diseases, 33, 386-392.
13. Ferrando, S. J., Wall, T. L., Batki, S. L., & Sorensen, J. L. (1996). Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. American Journal of Drug and Alcohol Abuse, 22, 475-487.
14. Gilbaldi M., Perrier D. (1975) Pharmokinetics. New York: Marcel Dekker.
15. Gordis, L., Markowitz, M., & Lilienfeld, A. M. (1969). The inaccuracy in using interviews to estimate patient reliability in taking medications at home. Medical Care, 7, 49-54.
16. Hambleton, J. (1997). Hematologic complications of HIV infection. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (Fifth ed., pp. 239-246). Philadelphia: W.B. Saunders.
17. Holland, D. T., Godredsen, K. A., & Connor, J. D. (1998). Simple reversed-phase high-performance liquid chromatography for the simultaneous determination of AZT and GAZT in urine. Unpublished manuscript.
18. Ickovics, J. R., Ethier, K. A., Koenig, L. J., Wilson, T. E., Walter, E. B., & Ferrando, S. (2000). Infant birth weight among women with or at high risk for HIV infection: The impact of clinical, behavioral, psychosocial, and demographic factors. Health Psychology, 19, 515-523.
19. Ickovics, J. R., Wilson, T. E., Royce, R. A., Minkoff, H. L., Fernandez, M. I., Fox-Tierney, R. et al. (2004). Prenatal and postpartum zidovudine adherence among pregnant women with HIV. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 30, 311-315.
20. Laine, C., Newschaffer, C. J., Zhang, D., Cosler, L., Hauck, W. W., & Turner, B. J. (2000). Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: A pharmacy claims-based analysis. Obstetrics and Gynecology, 95, 167-173.
21. Lim, L.L. & Volberding, P. A. (1994). The effect of zidovudine on erythrocyte mean corpuscular volume in asymptomatic HIV-infected individuals. Clinical Research and Regulatory Affairs, 11, 141-155.
22. Mellins, C. A., Havens, J. F., McCaskill, E. O., Leu, C. S., Brudney, K., & Chesney, M. A. (2002). Mental health, substance use and disclosure are significantly associated with the medical treatment adherence of HIV-infected mothers. Psychology, Health & Medicine, 7, 451-460.
23. Moneyham, L., Seals, B., Demi, A., Sowell, R., Cohen, L., & Guillory, J. (1996). Experiences of disclosure in women infected with HIV. Health Care for Women International. 17, 209-221.
24. O'Brien, K., Wortman, C. B., Kessler, R. C., & Joseph, J. G. (1998). Social relationships of men at risk for AIDS. Social Science & Medicine, 36, 1161-1167.
25. O'Sullivan, M. J., Boyer, P. J., Scott, G. B., Parks, W. P., Weller, S., Blum, M. R. et al. (1993). The pharmokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (Protocol 082). American Journal of Obstetrics and Gynecology, 168, 1510-1516.
26. Power, M. L., Holzman, G. B., & Schulkin, J. (2000). Knowledge and clinical practice regarding folic acid among obstetrician-gynecologists. Obstetrics and Gynecology, 95, 895-898.
27. Richman, D. D., Fischl, M. A., & Grieco, M. H. (1987). The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-bind, placebo-controlled trial. New England Journal of Medicine, 317, 192-197.
28. Romanelli, F., Empey, K., & Pomeroy, C. (2002). Macrocytosis as an indicator of medication (Zidovudine) adherence in patients with HIV infection. AIDS Patient Care and STDs, 16, 405-411.
29. Samet, J. H., Libman, H., Steger, K. A., Dhawan, R. K., Chen, J., Shevitz, A. H. et al. (1992). Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: A cross-sectional study in a municipal hospital clinic. The American Journal of Medicine, 92, 495-502.
30. Simoni, J. M., Demas, P., Mason, H. R. C., Drossman, J. A., & Davis, M. L. (2000). HIV Disclosure among women of African descent: Associations with coping, social support, and psychological adaptation. AIDS and Behavior, 4, 147-158.
31. Smith, M. Y., Rapkin, B. D., Morrison, A., & Kammerman, S. (1997). Zidovudine adherence in persons with AIDS: The relation of patient beliefs about medication to self-termination of therapy. Journal of General Internal Medicine, 12, 216-223.
32. Thomas, P. A., Weedon, J., Krasinkski, K., Abrams, E., Shaffer, N., Matheson, P. et al. (1994). Maternal predictors of perinatal human immunodeficiency virus transmission. Pediatric Infectious Disease Journal, 13, 489-495.
33. Wilson, T. E., Ickovics. J. R., Fernandez, M. I., Koenig, L. J., & Walter, E., for the Perinatal Guidelines Evaluation Study (2001). Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four U.S. states. American Journal of Obstetrics and Gynecology, 184, 1235-1240.
34. Wiznia, A. A., Crane, M., Lambert, G., Sansary, J., Harris, A., & Solomon, L. (1996). Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. Journal of the American Medical Association, 275, 1504-1506.
35. World Health Organization. (2004). Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. Department of HIV/AIDS and Department of Reproductive Health and Research, Geneva, Switzerland.